Overview

Study of PAT in Patients With Solid Tumor Cancers

Status:
Not yet recruiting

Trial end date:
2027-01-01

Target enrollment:

Participant gender:

Summary

This is a single center Phase I study with extension of peptide alarm therapy (PAT) administered by intratumoral (IT) injection during the 1st course of a standard of care intravenous PD-1/PD-L1 inhibitor for the treatment of locally advanced or metastatic solid tumor cancers that has failed to be controlled after one or more prior therapies including a previous PD-1/PD-L1 inhibitor

Phase:

Phase 1

Details

Lead Sponsor:

Masonic Cancer Center, University of Minnesota

Treatments:

Pembrolizumab